| UHC Medicaid Medical & Drug | Provider Administered Drugs – Site of Care – Community Plan Medical Benefit Drug Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | Repository Corticotropin Injections – Community Plan Medical Benefit Drug Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | RNA-Targeted Therapies (Amvuttra® and Onpattro®) – Community Plan Medical Benefit Drug Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | Saphnelo® (Anifrolumab-Fnia) – Community Plan Medical Benefit Drug Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | Scenesse® (Afamelanotide) – Community Plan Medical Benefit Drug Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | Sleep Studies – Community Plan Medical Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | Testosterone Replacement or Supplementation Therapy – Community Plan Medical Benefit Drug Policy | 2026-07-01 |
| UHC Medicaid Medical & Drug | Umbilical Cord Blood Harvesting and Storage for Future Use – Community Plan Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Adzynma (ADAMTS13, Recombinant-Krhn) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Korsuva® (Difelikefalin) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |